Lantheus price target raised to $78 from $73 at Citizens

Citizens analyst David Turkaly raised the firm’s price target on Lantheus (LNTH) to $78 from $73 and keeps an Outperform rating on the shares. Lantheus has a compelling radiopharmaceutical pipeline and is expected to resolve a key reimbursement headwind in late 2026, but its upcoming FY26 PYLARIFY guidance is likely to shape the investment narrative for this year, the analyst tells investors in a research note.